OSE Immunotherapeutics inks licensing deal with Chong Kun Dang Pharma
12 Nov 2019

French biotech company OSE Immunotherapeutics has announced a new licensing deal with South Korea based Chong Kun Dang (CKD) Pharmaceutical Corporation for Tedopi®, a combination of neoepitopes selected and optimized from five tumor antigens shown to generate a specific response of cytotoxic T cells versus cancer cells expressing at least one of these tumor associated antigens and an associated T-helper cell response, for potential registration and commercialization in Korea.

https://www.biospectrumasia.com/news/25/14868/ose-immunotherapeutics-inks-licensing-deal-with-chong-kun-dang-pharma.html